Pulmonx (NASDAQ:LUNG) Coverage Initiated at D. Boral Capital

Analysts at D. Boral Capital began coverage on shares of Pulmonx (NASDAQ:LUNG - Get Free Report) in a research report issued on Monday, Marketbeat.com reports. The firm set a "buy" rating and a $17.00 price target on the stock. D. Boral Capital's target price suggests a potential upside of 132.24% from the company's previous close.

Several other research analysts also recently commented on the company. Citigroup restated a "neutral" rating and issued a $7.50 target price (down previously from $17.00) on shares of Pulmonx in a research note on Wednesday, December 11th. Wells Fargo & Company cut their target price on Pulmonx from $10.00 to $8.00 and set an "equal weight" rating for the company in a research note on Wednesday, December 11th. Two analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $13.36.

Pulmonx Stock Performance

LUNG traded up $0.02 during trading hours on Monday, hitting $7.32. The stock had a trading volume of 166,518 shares, compared to its average volume of 333,798. The company's fifty day simple moving average is $6.99 and its 200 day simple moving average is $6.94. Pulmonx has a 1 year low of $5.46 and a 1 year high of $10.01. The stock has a market cap of $291.31 million, a PE ratio of -5.08 and a beta of 0.50. The company has a quick ratio of 6.77, a current ratio of 7.70 and a debt-to-equity ratio of 0.40.

Remove Ads

Pulmonx (NASDAQ:LUNG - Get Free Report) last announced its quarterly earnings data on Wednesday, February 19th. The company reported ($0.33) earnings per share for the quarter, topping the consensus estimate of ($0.45) by $0.12. Pulmonx had a negative return on equity of 55.36% and a negative net margin of 67.31%. The company had revenue of $23.77 million during the quarter, compared to analyst estimates of $22.29 million. Equities analysts anticipate that Pulmonx will post -1.55 earnings per share for the current year.

Insider Activity

In other news, General Counsel David Aaron Lehman sold 22,355 shares of Pulmonx stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $7.65, for a total transaction of $171,015.75. Following the completion of the sale, the general counsel now owns 175,496 shares in the company, valued at approximately $1,342,544.40. This trade represents a 11.30 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Steven S. Williamson sold 27,689 shares of Pulmonx stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $7.14, for a total value of $197,699.46. Following the sale, the chief executive officer now owns 194,342 shares of the company's stock, valued at approximately $1,387,601.88. This trade represents a 12.47 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 127,986 shares of company stock worth $986,673. 5.70% of the stock is currently owned by insiders.

Institutional Trading of Pulmonx

Several hedge funds and other institutional investors have recently bought and sold shares of the company. FMR LLC boosted its stake in Pulmonx by 11.2% in the third quarter. FMR LLC now owns 5,872,882 shares of the company's stock worth $48,686,000 after buying an additional 591,859 shares in the last quarter. Deerfield Management Company L.P. Series C purchased a new stake in Pulmonx in the fourth quarter worth approximately $10,421,000. BNP PARIBAS ASSET MANAGEMENT Holding S.A. boosted its stake in Pulmonx by 5.2% in the third quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 1,114,297 shares of the company's stock worth $9,238,000 after buying an additional 55,279 shares in the last quarter. JPMorgan Chase & Co. boosted its stake in Pulmonx by 2.4% in the third quarter. JPMorgan Chase & Co. now owns 1,055,522 shares of the company's stock worth $8,750,000 after buying an additional 25,002 shares in the last quarter. Finally, Geode Capital Management LLC boosted its stake in Pulmonx by 1.1% in the fourth quarter. Geode Capital Management LLC now owns 902,240 shares of the company's stock worth $6,128,000 after buying an additional 9,454 shares in the last quarter. Hedge funds and other institutional investors own 91.04% of the company's stock.

Pulmonx Company Profile

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.